MedTrace Logo

Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

NCT03914638 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-04-06

No results posted yet for this study

Summary

This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.

Conditions

Interventions

DRUG

Salbutamol 4Mg Tablet

Salbutamol 4 mg, three times daily

DRUG

Placebo oral capsule

Placebo, three times daily

Sponsors & Collaborators

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jan LS Thomsen, MD · University of Aarhus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-10-31
Completion
2021-10-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03914638 on ClinicalTrials.gov